MannKind Reports positive Q2 2026 Financial results and major FDA approvals for Afrezza and Furoscix

MannKind reported Q2 2026 total revenues grew 43% driven by gains from marketed products and announced three major catalysts, including FDA approvals for the pediatric indication of Afrezza, Furoscix ReadyFlow autoinjector, and positive nintedanib data.